Imbalance and gait disturbance from tyrosine kinase inhibition in hepatocellular cancer.

about

Exploratory analysis of early toxicity of sunitinib in advanced hepatocellular carcinoma patients: kinetics and potential biomarker value.

P2860

Q34504649-380BF4CF-762A-42DB-BC36-46D7D6605A67

P2860

Imbalance and gait disturbance from tyrosine kinase inhibition in hepatocellular cancer.

Item

http://www.wikidata.org/entity/Q42273555

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

2009年论文

@zh

2009年论文

@zh-cn

name

Imbalance and gait disturbance from tyrosine kinase inhibition in hepatocellular cancer.

@en

Imbalance and gait disturbance from tyrosine kinase inhibition in hepatocellular cancer.

@nl

type

Item

label

Imbalance and gait disturbance from tyrosine kinase inhibition in hepatocellular cancer.

@en

Imbalance and gait disturbance from tyrosine kinase inhibition in hepatocellular cancer.

@nl

prefLabel

Imbalance and gait disturbance from tyrosine kinase inhibition in hepatocellular cancer.

@en

Imbalance and gait disturbance from tyrosine kinase inhibition in hepatocellular cancer.

@nl

P1476

Imbalance and gait disturbance from tyrosine kinase inhibition in hepatocellular cancer.

@en

P2093

Andrew X Zhu

http://www.w3.org/2001/XMLSchema#string

Katherine M Krajewski

http://www.w3.org/2001/XMLSchema#string

Kuan-Chi Lai

http://www.w3.org/2001/XMLSchema#string

Marion C Stein

http://www.w3.org/2001/XMLSchema#string

Megan E Healy

http://www.w3.org/2001/XMLSchema#string

Rafael Rojas

http://www.w3.org/2001/XMLSchema#string

P2860

A reversible posterior leukoencephalopathy syndrome

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

VEGF enhances angiogenesis and promotes blood-brain barrier leakage in the ischemic brain.

Reversible posterior leukoencephalopathy syndrome after repeat intermediate-dose cytarabine chemotherapy in a patient with acute myeloid leukemia.

Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study.

SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer.

SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo.

In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.

Posterior reversible encephalopathy syndrome during sunitinib therapy.

Brain metastasis in renal cell cancer responding to sunitinib.

P2888

s12029-009-9086-7

P304

119-122

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S12029-009-9086-7

http://www.w3.org/2001/XMLSchema#string

P433

3-4

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Rebecca Miksad

P577

2009-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

38071450

http://www.w3.org/2001/XMLSchema#string

P698

19894033

http://www.w3.org/2001/XMLSchema#string

P932

3417813

http://www.w3.org/2001/XMLSchema#string

Imbalance and gait disturbance from tyrosine kinase inhibition in hepatocellular cancer.

about

P2860

P2860

Imbalance and gait disturbance from tyrosine kinase inhibition in hepatocellular cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P932